What is the best antibiotic for treating pneumonia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Best Antibiotic for Pneumonia

For outpatient community-acquired pneumonia in healthy adults without comorbidities, amoxicillin 1 gram three times daily for 5-7 days is the first-line treatment, with doxycycline 100 mg twice daily as the preferred alternative. 1, 2

Outpatient Treatment Algorithm

Healthy Adults Without Comorbidities (No Recent Antibiotics)

First-line choice:

  • Amoxicillin 1 gram orally every 8 hours for 5-7 days 1, 2
  • This targets Streptococcus pneumoniae, the most common pathogen (accounts for 48% of identified cases and two-thirds of bacteremic pneumonia) 1, 2

Alternative options:

  • Doxycycline 100 mg orally twice daily for 5-7 days 1, 2
  • Macrolide monotherapy (azithromycin 500 mg day 1, then 250 mg daily for 4 days OR clarithromycin 500 mg twice daily) ONLY if local pneumococcal macrolide resistance is documented <25% 1, 3, 2

Critical caveat: Macrolide monotherapy should be avoided in most settings due to widespread resistance (>25% in many regions) and risk of breakthrough pneumococcal bacteremia with resistant strains 2

Adults With Comorbidities or Recent Antibiotic Use (Within 90 Days)

Combination therapy is mandatory:

  • Amoxicillin-clavulanate 1-2 grams orally every 12 hours PLUS azithromycin 500 mg day 1, then 250 mg daily for 5-7 days 1, 2
  • Alternative: Cefuroxime, cefpodoxime, or cefaclor PLUS macrolide 1

Fluoroquinolone monotherapy alternative:

  • Levofloxacin 750 mg orally once daily for 5 days 1, 2
  • Moxifloxacin 400 mg orally once daily for 5-7 days 1
  • Warning: Reserve fluoroquinolones for patients who cannot use other options due to risks of tendinopathy, peripheral neuropathy, and CNS effects 2

Key principle: If antibiotics were used in the prior 90 days, select a different antibiotic class to reduce resistance risk 2

Hospitalized Non-ICU Patients

Preferred regimen:

  • Ceftriaxone 1-2 grams IV once daily OR cefotaxime 1-2 grams IV every 8 hours PLUS azithromycin 500 mg IV/PO once daily OR clarithromycin 500 mg IV/PO twice daily 1, 2
  • Alternative: Ampicillin-sulbactam 1.5-3 grams IV every 6 hours PLUS macrolide 1

Fluoroquinolone monotherapy alternative:

  • Levofloxacin 750 mg IV once daily 1
  • Moxifloxacin 400 mg IV once daily 1

Duration: 5-7 days for most cases 1, 2

Severe Pneumonia (ICU Patients)

Mandatory combination therapy:

  • β-lactam (ceftriaxone 2 grams IV daily, cefotaxime 2 grams IV every 8 hours, ampicillin-sulbactam 3 grams IV every 6 hours, OR piperacillin-tazobactam) PLUS either azithromycin 500 mg IV daily OR levofloxacin 750 mg IV daily 1

Never use fluoroquinolone monotherapy in ICU patients 1

Extended duration: 10 days for severe pneumonia; extend to 14-21 days if Legionella, Staphylococcus aureus, or gram-negative enteric bacilli are suspected or confirmed 1, 2

Hospital-Acquired Pneumonia (HAP)

Low Risk (No MRSA Risk Factors, Not High Mortality Risk)

Monotherapy options:

  • Piperacillin-tazobactam 4.5 grams IV every 6 hours 1
  • Cefepime 2 grams IV every 8 hours 1
  • Levofloxacin 750 mg IV daily 1
  • Imipenem 500 mg IV every 6 hours OR meropenem 1 gram IV every 8 hours 1

High Risk (MRSA Risk Factors or High Mortality Risk)

Combination therapy required:

  • Two antipseudomonal agents from different classes (avoid two β-lactams) PLUS MRSA coverage 1
  • MRSA coverage: Vancomycin 15 mg/kg IV every 8-12 hours (target trough 15-20 mg/mL) OR linezolid 600 mg IV every 12 hours 1

MRSA risk factors include: IV antibiotics within 90 days, unit where >20% of S. aureus isolates are methicillin-resistant, or prior MRSA detection 1

Pediatric Pneumonia

Children Under 3 Years

First-line:

  • Amoxicillin 80-100 mg/kg/day orally in 3 divided doses for 10 days 1
  • Rationale: Pneumococcus is the predominant bacterial pathogen in this age group 1

If inadequate Hib vaccination (<3 doses) OR concurrent purulent otitis media:

  • Amoxicillin-clavulanate 80 mg/kg/day (amoxicillin component) 1

Children Over 3 Years

If pneumococcal pneumonia suspected (lobar consolidation):

  • Amoxicillin 80-100 mg/kg/day orally in 3 divided doses for 10 days 1

If atypical pneumonia suspected (Mycoplasma or Chlamydophila):

  • Azithromycin 10 mg/kg day 1, then 5 mg/kg days 2-5 1
  • Alternative: Clarithromycin 15 mg/kg/day divided twice daily for 14 days 1

Critical Treatment Principles

Assessment of clinical response:

  • Evaluate at 48-72 hours (hospitalized) or 5-7 days (outpatients) 2
  • Fever should resolve within 2-4 days; pneumococcal pneumonia often responds within 24 hours 1, 2
  • Chest radiograph changes lag behind clinical improvement; do not repeat imaging in responding patients 1

Failure to respond indicates:

  • Incorrect diagnosis, host failure, inappropriate antibiotic selection, resistant pathogen, adverse drug reaction, or complication (empyema, abscess) 1
  • For non-severe pneumonia on amoxicillin monotherapy: add or substitute macrolide 1
  • For non-severe pneumonia on combination therapy: switch to respiratory fluoroquinolone 1
  • For severe pneumonia not responding: consider adding rifampicin 1

Switch from IV to oral therapy when:

  • Clinical improvement evident 1
  • Hemodynamically stable 1
  • Able to ingest medications 1
  • Typically occurs within 3-5 days 1

Common pitfalls to avoid:

  • Using macrolide monotherapy in areas with >25% pneumococcal macrolide resistance 2
  • Using macrolide monotherapy in patients with any comorbidities 2
  • Using fluoroquinolone monotherapy in ICU patients 1
  • Failing to cover MRSA in high-risk HAP patients 1
  • Using azithromycin or other macrolides in patients who received them within 90 days 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Community-Acquired Pneumonia Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Clarithromycin Dosage for Community-Acquired Pneumonia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.